Chief, Gastrointestinal Oncology Service; Head, Colorectal Oncology Section
I have been on the faculty of Memorial Sloan Kettering since 1989, and over the years I have treated thousands of people with common as well as rare gastrointestinal cancers. I have particular expertise in managing cancers of the colon and rectum, as well as rare tumors of the digestive tract such as carcinoid and pancreatic neuroendocrine tumors, and other digestive tract cancers such as liver, pancreas, stomach, and esophagus cancers. I also treat other neuroendocrine tumors such as adrenal cancers and pheochromocytomas.
Much of my career has also been dedicated to developing new drug therapies and treatment strategies for colorectal cancer, and I have tapped the vast resources of Memorial Sloan Kettering — from various clinical departments to the Human Oncology and Pathogenesis Program, the Sloan Kettering Institute, and The Rockefeller University — to create an integrated translational research program. As Chief of the Gastrointestinal Medical Oncology Service, I look forward to expanding this program even more in the years to come. I see enormous potential in using recent advances in the molecular analysis of tumors from individual patients to personalize and improve cancer treatment.
In addition to my role as Service Chief, I am Chair of the hospital’s Pharmacy and Therapeutics Committee and co-leader of the Colorectal Disease Management Team. I am also a Professor of Medicine at Weill Cornell Medical College.
Nationally, I serve on the National Cancer Institute (NCI) Rectal and Anal Cancer Task Force and am co-leader of the Alliance NCI Cooperative Research Group efforts in colon and rectal cancers. I also serve on three National Comprehensive Cancer Network (NCCN) guidelines committees: colorectal cancers, neuroendocrine cancers, and unknown primary cancers.
Since 1990 I have authored or co-authored more than 150 peer-reviewed journal articles on the development of new treatments for colorectal and other gastrointestinal cancers. I have also written numerous books, book chapters, monographs, and reviews on current and future treatment strategies for these diseases.
I am honored to have received various teaching and research awards over the years, as well as recognition for my work from such organizations as the American Cancer Society (Career Development Award) and Gilda’s Club (Advancement of Cancer Medicine Award).
- Clinical Expertise: Colorectal Cancer; Carcinoid Tumors; Islet Cell Carcinomas; Other Neuroendocrine Tumors; Other Gastrointestinal Cancers (Esophageal, Gastric, Pancreatic, Liver, Gall Bladder, Bile Duct, Anal); Unknown Primary Tumors; New Investigational Agents
- Awards and Honors: New York Magazine Top Doctors (2005-2008; 2011-2016)
- Languages Spoken: English
- Education: MD, Yale University
- Residencies: Internal Medicine - New York Hospital
- Fellowships: Hematology/Oncology - New York Hospital/Cornell University Medical Center
- Board Certifications: Internal Medicine; Medical Oncology; Hematology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Leonard Saltz
Clinical Trials Co-Investigated by Leonard Saltz
- A Phase I/II Study of SGI-110 plus Irinotecan with TAS-102 or Regorafenib for Previously Treated Metastatic Colorectal Cancer
- A Phase IB Study of Cobimetinib with Bevacizumab and Atezolizumab Immunotherapy in Patients with Progressive Metastatic Colorectal Cancer
- A Phase IB Study of RO6958688 plus Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
- A Phase II Study of Chemotherapy and Chemoradiation Followed by Surgery or Non-Operative Management in Patients with Stage II or III Rectal Cancer
- A Phase II Study of MEDI4736 in Patients with Advanced Colorectal Cancer with Certain Immunological Features
- A Phase II Study of Pembrolizumab Immunotherapy in Patients with Advanced Adrenocortical Cancer
- A Phase III Study of Encorafenib, Binimetinib, and Cetuximab for Patients with Metastatic Colorectal Cancer Containing Mutated BRAF
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more